Primary Site >> Colorectal Cancer

Gene >> PDGFRB

  • 1990
  • 1995
  • 1997
  • 1998
  • 2000
  • 2001
  • 2004
  • 2005
  • 2007
  • 2008
  • 2009
  • 2010
  • 2011
  • 2012
  • 2013
  • 2014
  • 2015
  • 2016
  • 2017
  • 2018
Ref: Expression of several growth factors and their receptor genes in human colon carcinomas.
PMID: 1980764
Ref: Receptor tyrosine kinases expressed in metastatic colon cancer.
PMID: 7896447
Ref: Isolation of a candidate tumor suppressor gene on chromosome 8p21.3-p22 that is homologous to an extracellular domain of the PDGF receptor beta gene.
PMID: 7898930
Ref: Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
PMID: 9046331
Ref: Molecular changes during the genesis of human gliomas.
PMID: 9407626
Ref: Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors.
PMID: 10974196
Ref: Construction of tumor-specific cells expressing a membrane-anchored single-chain Fv of anti-ErbB-2 antibody.
PMID: 11342269
Ref: Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents.
PMID: 11562278
Ref: Pleckstrin homology and phosphotyrosine-binding domain-dependent membrane association and tyrosine phosphorylation of Dok-4, an inhibitory adapter molecule expressed in epithelial cells.
PMID: 14963042
Ref: Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor.
PMID: 14985702
Ref: Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.
PMID: 15466784
Ref: Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
PMID: 15705896
Ref: Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
PMID: 15727903
Ref: In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models.
PMID: 15897558
Ref: Sunitinib: from rational design to clinical efficacy.
PMID: 17327610
Ref: Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content.
PMID: 17641778
Ref: Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy.
PMID: 18324358
Ref: mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer.
PMID: 19028276
Ref: TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche.
PMID: 19047154
Ref: Discovery and scoring of protein interaction subnetworks discriminative of late stage human colon cancer.
PMID: 19098285
Ref: Tyrosine kinase expression in pulmonary metastases and paired primary tumors.
PMID: 19948538
Ref: Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression.
PMID: 20358421
Ref: Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1alpha synthesis in HT-29 colon cancer cells.
PMID: 20599738
Ref: Angiogenic cells, macroparticles and RNA transcripts in laparoscopic vs open surgery for colorectal cancer.
PMID: 20676027
Ref: Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives.
PMID: 21028894
Ref: Dasatinib: an anti-tumour agent via Src inhibition.
PMID: 21226671
Ref: Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
PMID: 21670084
Ref: SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
PMID: 21691074
Ref: Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling.
PMID: 21949247
Ref: Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors.
PMID: 22174910
Ref: Activation of PDGFr-beta Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer.
PMID: 24212821
Ref: Refinement of the associations between risk of colorectal cancer and polymorphisms on chromosomes 1q41 and 12q13.13.
PMID: 22076443
Ref: A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.
PMID: 22421192
Ref: Regorafenib for cancer.
PMID: 22577890
Ref: PDGFRalpha/beta and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome.
PMID: 23146028
Ref: Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer.
PMID: 22821812
Ref: Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations.
PMID: 23053743
Ref: A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer.
PMID: 23108698
Ref: Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis.
PMID: 23188504
Ref: Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.
PMID: 23435872
Ref: PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells.
PMID: 23441134
Ref: Blockade of the PDGFR family together with SRC leads to diminished proliferation of colorectal cancer cells.
PMID: 23900414
Ref: Screening of hub genes and pathways in colorectal cancer with microarray technology.
PMID: 24504536
Ref: Discovery of colorectal cancer biomarker candidates by membrane proteomic analysis and subsequent verification using selected reaction monitoring (SRM) and tissue microarray (TMA) analysis.
PMID: 24687888
Ref: The prognostic value of the Na(+)/ H(+) exchanger regulatory factor 1 (NHERF1) protein in cancer.
PMID: 24878819
Ref: Involvement of the CREB5 regulatory network in colorectal cancer metastasis.
PMID: 25076032
Ref: Sunitinib mesylate inhibits proliferation of human colonic stromal fibroblasts in vitro and in vivo.
PMID: 25091988
Ref: Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.
PMID: 25069475
Ref: A novel germline mutation of PDGFR-beta might be associated with clinical response of colorectal cancer to regorafenib.
PMID: 25336117
Ref: Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
PMID: 26206183
Ref: MicroRNA-219-5p functions as a tumor suppressor partially by targeting platelet-derived growth factor receptor alpha in colorectal cancer.
PMID: 26458304
Ref: Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.
PMID: 26553611
Ref: Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
PMID: 26599335
Ref: EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.
PMID: 26810733
Ref: Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.
PMID: 26865419
Ref: Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing.
PMID: 27568332
Ref: Perivascular epithelioid cell tumor of the descending colon mimicking a gastrointestinal stromal tumor: a case report.
PMID: 27842558
Ref: Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis.
PMID: 28280620
Ref: A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity.
PMID: 28376187
Ref: The potential role of nintedanib in treating colorectal cancer.
PMID: 28649871
Ref: Targeted Delivery to Tumor-associated Pericytes via an Affibody with High Affinity for PDGFRbeta Enhances the in vivo Antitumor Effects of Human TRAIL.
PMID: 28740549
Ref: Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker.
PMID: 28770105
Ref: Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer.
PMID: 28965421
Ref: Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold.
PMID: 29482389
Ref: Plateletderived growth factor receptorbeta gene expression relates to recurrence in colorectal cancer.
PMID: 29498405
Ref: Expression of cancer-associated fibroblast markers in advanced colorectal cancer.
PMID: 29616101